The Subscription Period for Dicot"s Rights Issue Begins and The Company Invites to Investment Events
Today on September 3, 2019, the subscription period for the rights issue in Dicot AB (publ) ("Dicot" or the "Company") commences and continues until September 17, 2019. The Company hereby invites shareholders and investors to participate in investment meetings at Mangold's offices in Malmö and Stockholm.
Today is the first day of the subscription period for Dicot"s rights issue. The Company intends to use the proceeds from the rights issue to continue preclinical testing and prepare for a Phase-1 study. More information about the rights issue can be found on the Company"s website, www.dicot.se, and on Mangold's website, www.mangold.se. It is possible to subscribe for shares on Mangold's website using the electronic identification solution BankID.
Please see below for further information about each investment meeting and how to register.
Mangold, Stockholm
Date: September 11, 2019
Time: 11:30
Location: Engelbrektsplan 2, Stockholm
Register at: [email protected]
Mangold, Malmö
Date: September 12, 2019
Time: 11:45
Location: Elite Hotel Esplanade, Malmö
Register at: [email protected]
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
E-mail: [email protected]
www.dicot.se
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
E-mail: [email protected]
www.dicot.se
Filer
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
